文献速递淋巴瘤白血病

慢性淋巴细胞白血病中的T细胞:疾病的守护者还是驱动者?

T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
PubMed 文献 · Leukemia · 2020-05-26

本文综述慢性淋巴细胞白血病(CLL)中T细胞区室的异常改变,涵盖T细胞亚群分布、功能、耗竭状态及CLL药物对T细胞的影响,并讨论T细胞在CLL中促肿瘤或抗肿瘤的潜在病理作用及基于T细胞的免疫治疗近期结果。

要点

  • CLL患者血液中CD4+辅助性T细胞亚群数量增加,其细胞因子可在体外刺激CLL细胞存活与增殖。
  • CLL中抗原经验性CD8+ T细胞富集,并在小鼠模型中被证实可控制白血病。
  • CLL中T细胞表达PD-1等多种抑制性受体并功能丧失,继发淋巴器官中的耗竭表型较外周血更严重。

核心结论

  • CLL中T细胞是发挥促肿瘤旁观者作用还是具有抗肿瘤活性仍存争议,本综述讨论T细胞亚群在CLL中促进疾病进展还是控制疾病的潜在病理作用。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • CLL患者血液中CD4+辅助性T细胞亚群数量增加,T辅助细胞细胞因子在体外可刺激CLL细胞存活与增殖。
  • 小鼠异种移植模型中CLL细胞的存活与生长被证实依赖于活化的CD4+ T细胞。
  • 近年来CLL中抗原经验性CD8+ T细胞富集的证据积累,这些细胞在CLL小鼠模型中被证实可控制白血病。
  • CLL中T细胞表达PD-1等多种抑制性受体并失去功能能力,继发淋巴器官中的T细胞耗竭表型较外周血更严重。
  • CLL患者对CAR T细胞疗法反应不佳被提示与该耗竭表型相关,且CLL治疗药物可影响T细胞并可能影响治疗反应。

关键数值与推荐

  • 原文未报告具体数值标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, which is associated with profound alterations and defects in the immune system and a prevalent dependency on the microenvironmental niche. An abnormal T-cell compartment in the blood of CLL patients was already reported 40 years ago. Since then, our knowledge of T-cell characteristics in CLL has grown steadily, but the question of whether T-cells act as pro-tumoral bystander cells or possess anti-tumoral activity is still under debate. Increased numbers of CD4+ T-helper cell subsets are present in the blood of CLL patients, and T-helper cell cytokines have been shown to stimulate CLL cell survival and proliferation in vitro. In line with this, survival and growth of CLL cells in murine xenograft models have been shown to rely on activated CD4+ T-cells. This led to the hypothesis that T-cells are tumor-supportive in CLL. In recent years, evidence for an enrichment of antigen-experienced CD8+ T-cells in CLL has accumulated, and these cells have been shown to control leukemia in a CLL mouse model. Based on this, it was suggested that CD8+ T-cells recognize CLL-specific antigens and exert an anti-leukemia function. As described for other cancer entities, T-cells in CLL express multiple inhibitory receptors, such as PD-1, and lose their functional capacity, leading to an exhaustion phenotype which has been shown to be more severe in T-cells from secondary lymphoid organs compared with peripheral blood. This exhausted phenotype has been suggested to be causative for the poor response of CLL patients to CAR T-cell therapies. In addition, T-cells have been shown to be affected by drugs that are used to treat CLL, which likely impacts therapy response. This review provides an overview of the current knowledge about alterations of T-cells in CLL, including their distribution, function, and exhaustion state in blood and lymphoid organs, and touches also on the topic of how CLL drugs impact on the T-cell compartment and recent results of T-cell-based immunotherapy. We will discuss potential pathological roles of T-cell subsets in CLL and address the question of whether they foster progression or control of disease.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Roessner PM, Seiffert M. T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease? Leukemia. 2020. PMID: 32457353. doi:10.1038/s41375-020-0873-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。